RESUMEN
[Figure: see text].
Asunto(s)
COVID-19/metabolismo , Inflamación/metabolismo , Accidente Cerebrovascular Isquémico/metabolismo , Trombofilia/metabolismo , Anciano , Anciano de 80 o más Años , Sedimentación Sanguínea , Proteína C-Reactiva/metabolismo , COVID-19/complicaciones , Análisis por Conglomerados , Femenino , Ferritinas/metabolismo , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinógeno/metabolismo , Mortalidad Hospitalaria , Humanos , Interleucina-6/metabolismo , Accidente Cerebrovascular Isquémico/complicaciones , L-Lactato Deshidrogenasa/metabolismo , Recuento de Leucocitos , Modelos Logísticos , Aprendizaje Automático , Masculino , Persona de Mediana Edad , Infarto del Miocardio/complicaciones , Infarto del Miocardio/metabolismo , Tiempo de Tromboplastina Parcial , Embolia Pulmonar/complicaciones , Embolia Pulmonar/metabolismo , Estudios Retrospectivos , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Trombosis de la Vena/complicaciones , Trombosis de la Vena/metabolismoRESUMEN
Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor. While there are a number of in vivo rodent models for evaluating tumor biology and response to therapy, these models require significant time and resources. Here, we established the chick-embryo chorioallantoic (CAM) assay as an affordable and time efficient xenograft model for testing a variety of treatment approaches for DIPG. We found that patient-derived DIPG tumors develop in the CAM and maintain the same genetic and epigenetic characteristics of native DIPG tumors. We monitored tumor response to pharmaco- and radiation therapy by 3-D ultrasound volumetric and vasculature analysis. In this study, we established and validated the CAM model as a potential intermediate xenograft model for DIPG and its use for testing novel treatment approaches that include pharmacotherapy or radiation.
Asunto(s)
Antineoplásicos/farmacología , Neoplasias del Tronco Encefálico/genética , Membrana Corioalantoides/efectos de los fármacos , Membrana Corioalantoides/efectos de la radiación , Glioma Pontino Intrínseco Difuso/genética , Inhibidores de la Angiogénesis/farmacología , Inhibidores de la Angiogénesis/uso terapéutico , Animales , Antineoplásicos/uso terapéutico , Neoplasias del Tronco Encefálico/tratamiento farmacológico , Neoplasias del Tronco Encefálico/patología , Neoplasias del Tronco Encefálico/radioterapia , Línea Celular Tumoral , Embrión de Pollo , Membrana Corioalantoides/patología , Glioma Pontino Intrínseco Difuso/tratamiento farmacológico , Glioma Pontino Intrínseco Difuso/patología , Glioma Pontino Intrínseco Difuso/radioterapia , Humanos , Ratas , Ultrasonografía , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: Altered mental status (AMS) is a common neurological manifestation of COVID-19 infection in hospitalized patients. The principal causes of AMS have yet to be determined. We aimed to identify the common causes of AMS in patients with COVID-19 presenting to the emergency department with AMS on arrival. METHODS: We conducted a retrospective observational study of patients presenting with AMS to three New York hospitals, from March 1 to April 16, 2020. Underlying causes of AMS on arrival to the emergency department (ED) were categorized as (1) neurological causes (stroke, seizure, encephalitis); (2) metabolic encephalopathy; (3) indeterminant. Multivariable analysis was used to assess independent predictors. RESULTS: Overall, 166 patients presented to the ED with AMS. Metabolic encephalopathy was diagnosed as the cause in 154 (92.8%), with 118 (71.1%) categorized as multifactorial ME and 36 (21.7%) with single-cause ME. Hypoxia 103 (62.0%) and renal failure 75 (45.2%) were the most common underlying mechanisms. Neurological causes of AMS occurred in a total 20 patients (12%) and as the sole factor in 5 (3.0%); 10 (6.0%) cases were seizure related and 10 (6.0%) were cerebrovascular events. Of the 7 patients with indeterminant causes, only 1 was suspicious for encephalitis (0.6%). Age, pre-existing dementia and cerebrovascular disease, and impaired renal function were independent predictors of AMS. CONCLUSION: In patients with COVID-19, AMS on presentation to the ED is most frequently caused by metabolic encephalopathy (delirium). Seizures and cerebrovascular events contribute to a lesser degree; encephalitis appears rare.
Asunto(s)
COVID-19 , Trastornos Mentales , Servicio de Urgencia en Hospital , Humanos , Trastornos Mentales/epidemiología , Trastornos Mentales/etiología , SARS-CoV-2 , Convulsiones/epidemiología , Convulsiones/etiologíaRESUMEN
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is protean in its manifestations, affecting nearly every organ system. However, nervous system involvement and its effect on disease outcome are poorly characterized. The objective of this study was to determine whether neurologic syndromes are associated with increased risk of inpatient mortality. METHODS: A total of 581 hospitalized patients with confirmed SARS-CoV-2 infection, neurologic involvement, and brain imaging were compared to hospitalized non-neurologic patients with coronavirus disease 2019 (COVID-19). Four patterns of neurologic manifestations were identified: acute stroke, new or recrudescent seizures, altered mentation with normal imaging, and neuro-COVID-19 complex. Factors present on admission were analyzed as potential predictors of in-hospital mortality, including sociodemographic variables, preexisting comorbidities, vital signs, laboratory values, and pattern of neurologic manifestations. Significant predictors were incorporated into a disease severity score. Patients with neurologic manifestations were matched with patients of the same age and disease severity to assess the risk of death. RESULTS: A total of 4,711 patients with confirmed SARS-CoV-2 infection were admitted to one medical system in New York City during a 6-week period. Of these, 581 (12%) had neurologic issues of sufficient concern to warrant neuroimaging. These patients were compared to 1,743 non-neurologic patients with COVID-19 matched for age and disease severity admitted during the same period. Patients with altered mentation (n = 258, p = 0.04, odds ratio [OR] 1.39, confidence interval [CI] 1.04-1.86) or radiologically confirmed stroke (n = 55, p = 0.001, OR 3.1, CI 1.65-5.92) had a higher risk of mortality than age- and severity-matched controls. CONCLUSIONS: The incidence of altered mentation or stroke on admission predicts a modest but significantly higher risk of in-hospital mortality independent of disease severity. While other biomarker factors also predict mortality, measures to identify and treat such patients may be important in reducing overall mortality of COVID-19.
Asunto(s)
COVID-19/mortalidad , Confusión/fisiopatología , Trastornos de la Conciencia/fisiopatología , Mortalidad Hospitalaria , Accidente Cerebrovascular/fisiopatología , Anciano , Anciano de 80 o más Años , Ageusia/epidemiología , Ageusia/fisiopatología , Anosmia/epidemiología , Anosmia/fisiopatología , Ataxia/epidemiología , Ataxia/fisiopatología , COVID-19/fisiopatología , Confusión/epidemiología , Trastornos de la Conciencia/epidemiología , Enfermedades de los Nervios Craneales/epidemiología , Enfermedades de los Nervios Craneales/fisiopatología , Delirio/epidemiología , Delirio/fisiopatología , Femenino , Cefalea/epidemiología , Cefalea/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Parestesia/epidemiología , Parestesia/fisiopatología , Disautonomías Primarias/epidemiología , Disautonomías Primarias/fisiopatología , Recurrencia , SARS-CoV-2 , Convulsiones/epidemiología , Convulsiones/fisiopatología , Accidente Cerebrovascular/epidemiología , Vértigo/epidemiología , Vértigo/fisiopatologíaRESUMEN
BACKGROUND: This study evaluates the mortality risk of patients with emergent large vessel occlusion (ELVO) and COVID-19 during the pandemic. METHODS: We performed a retrospective cohort study of two cohorts of consecutive patients with ELVO admitted to a quaternary hospital from March 1 to April 17, 2020. We abstracted data from electronic health records on baseline, biomarker profiles, key time points, quality measures and radiographic data. RESULTS: Of 179 patients admitted with ischemic stroke, 36 had ELVO. Patients with COVID-19 and ELVO had a higher risk of mortality during the pandemic versus patients without COVID-19 (OR 16.63, p = 0.004). An age-based sub-analysis showed in-hospital mortality in 60% of COVID-19 positive patients between 61-70 years-old, 66.7% in between 51-60 years-old, 50% in between 41-50 years-old and 33.3% in between 31-40 years old. Patients that presented with pulmonary symptoms at time of stroke presentation had 71.4% mortality rate. 27.3% of COVID-19 patients presenting with ELVO had a good outcome at discharge (mRS 0-2). Patients with a history of cigarette smoking (p = 0.003), elevated d-dimer (p = 0.007), failure to recanalize (p = 0.007), and elevated ferritin levels (p = 0.006) had an increased risk of mortality. CONCLUSION: Patients with COVID-19 and ELVO had a significantly higher risk for mortality compared to COVID-19 negative patients with ELVO. A small percentage of COVID-19 ELVO patients had good outcomes. Age greater than 60 and pulmonary symptoms at presentation have higher risk for mortality. Other risk factors for mortality were a history of cigarette smoking, elevated, failure to recanalize, elevated d-dimer and ferritin levels.